Drug Profile
Anti-inflammatory therapeutic - Actelion Ppharmaceuticals
Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for phase-I development in Inflammation in Switzerland
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 25 Oct 2016 Phase-I clinical trials in Inflammation in Switzerland (unspecified route)